Benzinga
Benzinga
Benzinga
mercoledì, settembre 16

Cue Biopharma Inc

CUENASDAQ
Trade with Public
Trade with Public
$31.64
1.093.57%
In chiusura: Sep 15, 5:00 PM EST
$31.00
-0.64-2.02%
Post-mercato: 7:53 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Cue Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cue Biopharma (CUE).

Price Target Range — 6 Quarters

Analyst Consensus — 7 Analysts

2S.Buy
5Buy
Consensus RatingBuy# Analysts7Avg. Consensus PT$133Upside to Avg. PT+328.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Aug 25, 2025LUCID CAPITAL MARKETSDev Prasad InitiateBuy$4
Apr 2, 2025Citizens Capital MarketsReni BenjaminMaintainedMarket Outperform$2
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
LUCID CAPITAL MARKETS Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $4

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Buy rating and announces Price Target of $4.
Benzinga Newsdesk

PRO
Citizens Capital Markets Reiterates Market Outperform on Cue Biopharma, Maintains $2 Price Target

Citizens Capital Markets analyst Reni Benjamin reiterates Cue Biopharma (NASDAQ:CUE) with a Market Outperform and maintains $2 price target.
Benzinga Newsdesk

PRO
Stifel Maintains Buy on Cue Biopharma, Lowers Price Target to $4

Stifel analyst Stephen Willey maintains Cue Biopharma (NASDAQ:CUE) with a Buy and lowers the price target from $8 to $4.
Benzinga Newsdesk

Cue Biopharma, Inc. Reports Q2 Loss, Tops Revenue Estimates

Cue Biopharma, Inc. (NASDAQ: CUE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.
Zacks

PRO
JMP Securities Maintains Market Outperform on Cue Biopharma, Lowers Price Target to $2

JMP Securities analyst Reni Benjamin maintains Cue Biopharma (NASDAQ:CUE) with a Market Outperform and lowers the price target from $15 to $2.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Cue Biopharma, Lowers Price Target to $3

Piper Sandler analyst Edward Tenthoff maintains Cue Biopharma (NASDAQ:CUE) with a Overweight and lowers the price target from $8 to $3.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved